An exploratory analysis of the competing effects of alcohol use and advanced hepatic fibrosis on serum HDL

Augustin G. L. Vannier1,2,3 · Amanda PeBenito1,2,3 · Vladislav Fomin1,2,3 · Raymond T. Chung1,2,3 · Esperance Schaefer1,2,3 · Russell P. Goodman1,2,3 · Jay Luther1,2,3

Received: 10 March 2021 / Accepted: 22 June 2021 / Published online: 1 July 2021 © The Author(s) 2021

Abstract
While alcohol use has been shown to increase serum HDL, advanced liver disease associates with decreased serum HDL. The combined influence of alcohol consumption and liver fibrosis is poorly defined. In this study, we sought to investigate the competing effects of alcohol use and hepatic fibrosis on serum HDL and to determine if the presence of advanced hepatic fibrosis ablates the reported effect of alcohol consumption on serum HDL. We performed a cross-sectional, exploratory analysis examining the interaction between alcohol use and advanced hepatic fibrosis on serum HDL levels in 10,528 patients from the Partners Biobank. Hepatic fibrosis was assessed using the FIB-4 index. We excluded patients with baseline characteristics that affect serum HDL, independent of alcohol use or the presence or advanced hepatic fibrosis. We observed an incremental correlation between increasing HDL levels and amount of alcohol consumed (P < 0.0001), plateauing in those individuals who drink 1–2 drinks per day. Contrastingly, we found a negative association between the presence of advanced hepatic fibrosis and lower HDL levels, independent of alcohol use (beta coefficient: -0.011075, SEM0.003091, P value: 0.0001). Finally, when comparing subjects with advanced hepatic fibrosis who do not use alcohol to those who do, we observed that alcohol use is associated with increased HDL levels (54.58 mg/dL vs 67.26 mg/dL, p = 0.0009). This HDL-elevating effect of alcohol was more pronounced than that seen in patients without evidence of advanced hepatic fibrosis (60.88 mg/dL vs 67.93 mg/dL, p < 0.0001). Our data suggest that the presence of advanced hepatic fibrosis does not blunt the HDL-elevating effect of alcohol use.

Keywords Alcoholic-associated liver disease · Alcohol use · HDL

Introduction
Excessive alcohol use is a frequent cause of morbidity and mortality worldwide. In fact, alcohol use is one of the most common causes of deaths and disability-associated life years (DALYs) [1], as it is mechanistically linked with the development of multiple diseases. Most notably, Alcohol-associated Liver Disease (ALD) is one of the most common manifestations of alcohol misuse and accounts for close to 1/3rd of all alcohol-related deaths [1]. Interestingly, multiple observational studies have demonstrated a positive association between moderate alcohol use and high-density lipoprotein (HDL) levels [2–6].

The regulation of serum HDL, a cholesterol subtype, is complex. The liver accounts for a majority of the total serum HDL levels and is intimately involved in all aspects of HDL regulation, from synthesis to transport to metabolism. Accordingly, previous studies have demonstrated reduced HDL levels in patients with both acute and chronic liver diseases [7–9]. Additionally, data suggest an inverse association between HDL levels and hepatic function. Specifically, reduced serum HDL levels have been associated with severity of liver disease, the presence of liver-related complications and mortality in patients with cirrhosis [10].
Despite the observed associations of alcohol and liver disease with serum HDL, there are limited data examining the competing effects of each in a well-characterized cohort. To address this question, we investigated the interaction between alcohol use and the presence of advanced hepatic fibrosis in a large cohort of patients unaffected by major sources of HDL variation: hepatitis B or C infection, primary biliary cholangitis, poor glycemic control, obesity, heavy smoking or lipid-lowering medications. Thus, we sought to isolate the combined effects of alcohol and fibrosis on serum HDL.

**METHODS**

**Clinical database**

Clinical data were obtained from the Partners Biobank [11], which is a large integrated database from Mass General Brigham healthcare, comprised of approximately 121,691 consented subjects with variable clinical data that is available. Within the Mass Hospital Brigham system, there is an online platform which allows for a detailed search of this cohort to allow identification of patients that have available data that fits the proposed clinical question. We queried this database to identify patients that met inclusion criteria, which are detailed below. These criteria were determined a priori. Data were derived from electronic health records, which include patient data since 1990. Informed consent was obtained from all study participants and/or their guardians.

**Patient selection**

Patients were included in the study if they had all of the following available for analysis: 1) lipid panels, 2) fully completed alcohol questionnaires; and 3) clinical data to allow for noninvasive assessment of hepatic fibrosis. Once patients were identified, we pulled demographics, medication, laboratory and alcohol use data. The most recent laboratory data available in the dataset were used for analysis. The date of questionnaire completion is not recorded in the Biobank dataset; therefore, we were unable to ascertain the timing between questionnaire completion and laboratory evaluation. The alcohol questionnaire administered for this study asked the following question: “During the past year, how many alcoholic drinks (glass/bottle/can of beer; 4 oz glass of wine; drink or shot of liquor) did you usually drink in a typical week?”. Participants were given the following options: 1) None, or less than one per month, 2) 1–3 per month, 3) 2–4 per week, 4) 5–6 per week, 5) 1–2 per day, 6) 3–4 per day, 7) 5–6 per day, or 9) more than 6 per day.

We excluded variables which have been shown to affect serum HDL levels, in order to isolate the effects of alcohol and fibrosis on HDL. Therefore, patients were excluded if they had obesity (BMI ≥ 30), poor glycemic control (Hemoglobin A1C > 6.5), a smoking history greater than 75 pack-years, or used lipid-lowering medications. In addition, we excluded patients with a liver disease known to affect HDL independently of fibrosis. We therefore excluded patients with primary biliary cholangitis or evidence of prior or active Hepatitis B or C infection [12–15].

**Assessment of hepatic fibrosis**

The Fibrosis-4 Index (FIB-4) was used to determine the presence of advanced hepatic fibrosis. The FIB-4 was calculated using the following formula: (Age [years] * AST)/ (Platelet count[10 × 109]*√(ALT).

Patients with FIB-4 score of greater than or equal to 3.25 were defined as having advanced hepatic fibrosis, as this cut-off value has been shown to have high diagnostic accuracy for advanced hepatic fibrosis in patients with ALD[16]. This value has been associated with METAVIR, Batts and Ludwig, or Scheuer stages F3 through F4 or Ishak stages F4 through F6. [17].

**Statistical analyses**

Comparisons between two groups were performed with unpaired, two tailed, Welch t tests and comparisons among three or more groups were performed with one-way ANOVA with follow-up Tukey tests. Comparison of categorical variables was performed with Fisher’s exact test. Risk factors for severe liver disease were examined with the use of univariate and multivariate logistic regression; all factors in the univariate analysis were included in the multivariate analysis. A beta coefficient value was calculated to measure the degree to which each variable influenced the severity of liver disease, with \( P < 0.05 \) considered significant. All analyses were conducted using GraphPad Prism (San Diego, CA).

**Results**

**Demographics**

The total cohort of patients included in this analysis consisted of 10,528 patients (Fig. 1, Table 1). The majority of patients studied were middle-age (52.4 years), female (70.2%) and white (93.5%). As noted previously, patients were not obese and had no history of significant insulin resistance or smoking. Approximately one-half of the patients included in the analysis drank either 0–1 drinks per month or 2–4 drinks per week, with a minority of patients (3.5%) drinking 3 or more alcohol beverages per day.
**Table 1** Patient demographics

|                         | Total       |
|-------------------------|-------------|
| N                       | 10,528      |
| Age                     | 52.4        |
| Sex (%Female)           | 70.2        |
| BMI                     | 24.0        |
| HgbA1c                  | 5.3         |
| LDL                     | 103.9       |
| Triglycerides           | 97.9        |
| Race/Ethnicity          |             |
| White (%)               | 93.5        |
| Asian (%)               | 3.8         |
| Black (%)               | 2.7         |
| Hispanic (%)            | 1.8         |
| Alcohol use N (%)       |             |
| 0–1 /month              | 2565 (24.4) |
| 1–3 /month              | 1422 (13.5) |
| 1 /week                 | 969 (9.2)   |
| 2–4 /week               | 2426 (23)   |
| 5–6 /week               | 1627 (15.5) |
| 1–2 /day                | 1155 (11)   |
| 3–4 /day                | 280 (2.7)   |
| 5–6 /day                | 47 (0.4)    |
| > 6 /day                | 37 (0.4)    |

N = number; BMI = body mass index; HgbA1c = hemoglobin A1c; LDL: low-density lipoprotein
With regards to liver disease severity, 373 patients had serologic evidence of advanced hepatic fibrosis while 10,155 subjects did not. These populations differed in multiple ways (Table 2), including age (mean age 58.9 versus 52). The cohort of patients with available data to study liver disease severity had more women than men (70% female) and while this distribution was also observed in the group without liver disease, there was a higher representation of males in the fibrosis group (53.2% female). The two groups in our hepatic fibrosis analyses were similar in terms of their BMI and racial and ethnic distributions.

Incremental increase in serum HDL levels associated with alcohol use

Previous data have suggested a positive correlation between alcohol use and serum HDL levels [2–4]. To investigate this in our cohort, we examined the association of HDL levels with quantity of alcohol consumed. While patients that abstained from alcohol or had less than one drink per month (n = 2565) had an average HDL of 59.76 mg/dL, those that drank one or more alcoholic drink daily (n = 1519) had an average HDL of 70.56 mg/dL (P < 0.0001). Similarly, we found a difference in HDL levels in those patients with severe (3–6 drinks per day), moderate (2–14 drinks/week) and minimal (0–1 drinks/week) alcohol consumption (P < 0.0001) (Fig. 2a). Furthermore, we found that HDL levels steadily rose incrementally with drink quantity, plateauing in those individuals who drink 1–2 drinks per day (Fig. 2b). Taken together, these data suggest a positive association between alcohol use and serum HDL levels.

Advanced hepatic fibrosis associates with reduced serum HDL levels

We next sought to examine whether the presence of advanced hepatic fibrosis was associated with serum HDL levels in our cohort. To investigate this, we defined the presence of advanced hepatic fibrosis as those patients with a FIB-4 score of ≥ 3.25. In the 373 patients with evidence of advanced hepatic fibrosis, HDL levels were lower compared to the 10,155 subjects without evidence of advanced hepatic fibrosis (Fig. 3) (mean HDL 59.97 mg/dL vs. 64.46 mg/dL, p < 0.0001). Furthermore, in a univariate analysis, we found that HDL was associated significantly with liver disease severity, as did age and gender in our cohort (Table 3). In a multivariate analysis accounting for age and gender, we found that the association between HDL levels and advanced hepatic fibrosis maintained significance (Beta coefficient: -0.01175, SEM: 0.003091, P value: 0.0001). Taken together, these data support the negative association between the presence of advanced hepatic fibrosis and serum HDL levels.

The combined effect of alcohol use and advanced hepatic fibrosis on serum HDL levels

Given the observed competing effects of alcohol and advanced hepatic fibrosis on serum HDL levels in our cohort, we next determined the combined effect of these variables on serum HDL. To accomplish this, we stratified subjects by both alcohol use and the presence or absence of advanced hepatic fibrosis. In subjects with minimal alcohol use, defined as less than 1 drink per week (0–3 per month), those with advanced hepatic fibrosis have significantly lower HDL levels compared to those patients without advanced fibrosis (Fig. 4). However, when examining patients with significant alcohol use (3 or more drinks per day) this relationship was lost and both patients with and without advanced hepatic fibrosis had comparable HDL levels (67.26 mg/dL vs 67.93 mg/dL, p = 0.9997). Likewise, when comparing subjects with significant alcohol use (3 or more drinks per day) this relationship was lost and both patients with and without advanced hepatic fibrosis had comparable HDL levels (54.58 mg/dL vs 67.26 mg/dL, p = 0.0078). This HDL-elevating effect of alcohol was comparable and even greater than that seen in patients without advanced hepatic fibrosis (60.88 mg/dL vs 67.93 mg/dL, p < 0.0001). Taken together, these data suggest that while liver disease is associated with lower HDL levels, it does not blunt the HDL-elevating effect of alcohol use.

Table 2  Patient demographics based on the presence or absence of hepatic fibrosis

|              | No fibrosis | Fibrosis | P value |
|--------------|-------------|----------|---------|
| N            | 10,032      | 496      |         |
| Age          | 52.0        | 58.9     | < 0.0001|
| Sex (%Female)| 71.0        | 53.2     | < 0.0001|
| BMI          | 24.0        | 24.0     | 0.86    |
| Hgb A1c      | 5.3         | 5.3      | 0.37    |
| LDL          | 103.9       | 103.1    | 0.62    |
| Triglycerides| 97.4        | 109.0    | < 0.0001|
| Race/Ethnicity| 1.0        |          |         |
| White (%)    | 93.4        | 94.2     |         |
| Asian (%)    | 3.9         | 3.0      |         |
| Black (%)    | 2.7         | 2.8      |         |
| Hispanic (%) | 1.8         | 2.3      |         |

N = number; BMI = body mass index; HgbA1c = hemoglobin A1c; LDL: low-density lipoprotein.
Discussion

In our exploratory analysis of a large cohort of patients, we reaffirmed the findings that heavier alcohol use associates with increased HDL levels and that the presence of advanced hepatic fibrosis associates with reduced serum HDL levels. In addition, our analysis highlights the fact
that the HDL-elevating effect of alcohol is maintained in those patients with evidence for advanced hepatic fibrosis. While multiple previous studies have documented the effects of alcohol and liver disease on serum HDL, there are limited and remote data examining their competing effects in the same cohort [18, 19]. In our exploratory analysis, we found that the ability of alcohol to raise HDL levels occurred despite the presence of advanced hepatic fibrosis. While there may be multiple biological explanations for this finding, our results raise the possibility that the effect of alcohol on serum HDL is regulated in a liver-independent manner. The critical role of the liver in regulation of HDL is not debated. Decades of mechanistic and epidemiological studies have demonstrated the importance of preserved hepatic functioning in all aspects of HDL regulation, from synthesis to transport to metabolism [20]. For example, previous translational work has suggested that alcohol increases the transport rates of apoA-I and apoA-II, two major HDL lipoproteins [21]. Mechanistic work has also identified the effect of alcohol on reverse cholesterol transport, mediated in part by PPAR-γ, which impacts serum HDL levels [22]. Additionally, certain data suggest an inhibitory effect of alcohol on the activity of cholesteryl-ester transfer protein (CEPT), a key transporter of cholesterol from HDL to LDL, leading to higher HDL levels [23]. These data reinforce the importance of preserved hepatic function in the regulation of HDL. Patients with advanced hepatic fibrosis have reduced liver function and are therefore expected to have a reduced ability to modulate HDL in a liver-dependent manner in response to alcohol. However, we did not find this in our study. Because patients with advanced hepatic fibrosis and active alcohol use had significantly higher serum HDL levels compared to those with advanced hepatic fibrosis who were not drinking, it is possible that novel and liver-independent pathways also contribute to alcohol’s effect on serum HDL. Further mechanistic work is needed to better understand this relationship.

The association of alcohol use with increased HDL levels is of unclear clinical impact. Several studies have found that low to moderate alcohol consumption is associated with improved cardiovascular-related survival compared with abstainers and heavy drinkers [1, 24, 25] and that this observed association may be related to elevated HDL levels in patients with alcohol use. However, some studies challenge this hypothesis. In particular, Mendelian randomization studies have shown that genetic variants which naturally increase HDL levels do not confer a cardioprotective benefit [26] and that genetic variants linked with non-drinking or low amounts of alcohol consumption are associated with favorable cardiovascular profiles [27]. Similarly, there is little evidence that pharmacotherapy directly targeting HDL is associated with improved cardiovascular outcomes. Further studies examining the effect of elevated HDL levels in patients with alcohol use and liver disease on cardiovascular outcomes are warranted.

Despite our findings, certain limitations of our exploratory analysis must be highlighted. First, we relied on FIB-4 scores as a marker of the presence of hepatic fibrosis. While this marker has been validated and used in numerous epidemiological studies [28–30], it is not the gold standard for hepatic fibrosis assessment and was originally validated in liver disease not caused by alcohol. However, the FIB-4 index was shown to have diagnostic accuracy for identifying advanced hepatic fibrosis in patients with ALD [16]. Second, we were unable to determine the interval time between completion of the alcohol questionnaire and laboratory evaluation. It is therefore possible that patients meaningfully changed their alcohol consumption habits from the time of completing the questionnaire to when we evaluated HDL levels, which may have affected the results. Finally, the vast majority of patients in our analysis were white and female,
limiting the ability to generalize our results and raising the possibility of selection bias. Additionally, our observed prevalence of advanced hepatic fibrosis (\sim 4\%) is less than what is reported in the literature [31], further amplifying the possibility of selection bias.

In summary, our exploratory investigation into the effects of alcohol and liver disease on HDL levels suggest that the presence of liver disease does not blunt the effect of alcohol on HDL, raising the possibility that the alcohol elevating effect on HDL occurs independently of preserved liver function.

Author’s contributions AV, APB, RTC, ES, RG and JL conceived and designed the project, collected and interpreted the data and prepared the final manuscript. All authors read and approved the final manuscript.

Funding This work was supported by a National Institutes of Health grant to RPG (K08DK115881).

Declarations

Confict of interest The authors declare that they have no competing interests.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Griswold MG, Fullman N, Hawley C, Arian N, Zimsen SRM, Tymeson HD, et al. Alcohol use and burden for 195 countries and territories, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet [Internet]. Lancet Publishing Group; 2018 [cited 2020 Dec 16]:392:1015–35.
2. Huang S, Li J, Shearer GC, Lichtenstein AH, Zheng X, Wu Y, et al. Longitudinal study of alcohol consumption and HDL concentrations: A community-based study. Am J Clin Nutr [Internet]. American Society for Nutrition; 2017 [cited 2020 Aug 10]:105:905–12. Available from: /pmc/articles/PMC5366050/?report=abstract
3. Rosoff DB, Charlet K, Jung J, Lee J, Muench C, Luo A, et al. Association of High-Intensity Binge Drinking With Lipid and Liver Function Enzyme Levels. JAMA Netw open [Internet]. NLM (Medline); 2019 [cited 2020 Dec 23]:2:e195844. Available from: https://jamanetwork.com/
4. Spaggiari G, Cignarelli A, Sansone A, Baldi M, Santi D. To beer or not to beer: A meta-analysis of the effects of beer consumption on cardiovascular health. Li Y, editor. PLoS One [Internet]. Public Library of Science; 2020 [cited 2020 Dec 17]:15:e0233619. Available from: https://dx.plos.org/https://doi.org/10.1371/journal.pone.0233619
5. Gaziano JM, Buring JE, Breslow JL, Goldhaber SZ, Rosner B, VanDenburgh M, et al. Moderate Alcohol Intake, Increased Levels of High-Density Lipoprotein and Its Subfractions and Decreased Risk of Myocardial Infarction. N Engl J Med [Internet]. Massachusetts Medical Society; 1993 [cited 2020 Dec 16]:329:1829–34. Available from: https://www.nejm.org/doi/pdf/10.1056/NEJM199312163292501
6. Linn S, Carroll M, Johnson C, Fulwood R, Kalsbeek W, Briefel R. High-density lipoprotein cholesterol and alcohol consumption in US White and Black adults: Data from NHANES II. Am J Public Health [Internet]. American Public Health Association; 1993 [cited 2021 Feb 22]:83:811–6. Available from: http://ajph.aphapublications.org/
7. Etoogo-Asse FE, Vincent RP, Hughes SA, Auzinger G, Le Roux CW, Wendon J, et al. High density lipoprotein in patients with liver failure: Relation to sepsis, adrenal function and outcome of illness. Liver Int [Internet]. Liver Int; 2012 [cited 2020 Dec 23]:32:128–36. Available from: https://pubmed.ncbi.nlm.nih.gov/22098564/
8. Habib A, Mihas AA, Abou-Assi SG, Williams LM, Gavis E, Pandak WM, et al. High-density lipoprotein cholesterol as an indicator of liver function and prognosis in noncholestatic cirrhotics. Clin Gastroenterol Hepatol. W.B. Saunders; 2005;3:286–91.
9. Ciccognani C. Serum Lipid and Lipoprotein Patterns in Patients With Liver Cirrhosis and Chronic Active Hepatitis. Arch Intern Med [Internet]. American Medical Association (AMA); 1997 [cited 2021 Feb 22]:157:792. Available from: https://jamanetwork.com/
10. Trieb M, Rainer F, Stadlbauer V, Douschan P, Horvath A, Binder L, et al. HDL-related biomarkers are robust predictors of survival in patients with chronic liver failure. J Hepatol. Elsevier B.V.; 2020;73:113–20.
11. Gainer VS, Cagan A, Castro VM, Duey S, Ghosh B, Goodson AP, et al. The biobank portal for partners personalized medicine: A query tool for working with consented biobank samples, genotypes and phenotypes using i2b2. J Pers Med [Internet]. MDPI AG; 2016 [cited 2020 Dec 16]:6. Available from: /pmc/articles/PMC4810390/?report=abstract
12. Butt AA, Yan P, Simon TG, Chung RT, Abou-Samra AB. Changes in circulating lipids levels over time after acquiring HCV infection: Results from ERCHIVES, BMC Infect Dis [Internet]. BioMed Central Ltd.; 2015 [cited 2021 Feb 17]:15. Available from: https://pubmed.ncbi.nlm.nih.gov/26558512/
13. Hsu C-S, Liu C-H, Wang C-C, Tseng T-C, Liu C-J, Chen C-L, et al. Impact of hepatitis B virus infection on metabolic profiles and modifying factors. J Viral Hepat [Internet]. Blackwell Publishing Ltd; 2012 [cited 2021 Feb 17]:19:e48–57. Available from: http://doi.wiley.com/https://doi.org/10.1111/j.1365-2893.2011.01535.x
14. Jahn CE, Schaefer EJ, Taam LA, Hoofnagle JH, Lindgren FT, Albers JI, et al. Lipoprotein abnormalities in primary biliary cirrhosis. Association with hepatic lipase inhibition as well as altered cholesterol esterification. Gastroenterology. W.B. Saunders; 1985;89:1266–78.
15. Speliotes EK, Balkrishnan M, Friedman LS, Corey KE. Treatment of Dyslipidemia in Common Liver Diseases. Clin Gastroenterol Hepatol [Internet]. W.B. Saunders; 2018 [cited 2021 Feb 22];16:1189–96. Available from: /pmc/articles/PMC6558967/
16. Thiele M, Madsen BS, Hansen JF, Detlefsen S, Antonsen S, Krag A. Accuracy of the Enhanced Liver Fibrosis Test vs FibroTest, Elastography and Indirect Markers in Detection of Advanced Fibrosis in Patients With Alcoholic Liver Disease. Gastroenterology [Internet]. W.B. Saunders; 2018 [cited 2021 May
21].154:1369–79. Available from: https://pubmed.ncbi.nlm.nih.gov/29317276/

17. Vallet-Pichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A, Dhaliuin-Venier V, et al. FIB-4: An inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and FibroTest. Hepatology [Internet]. Hepatology; 2007 [cited 2020 Dec 17];46:32–6. Available from: https://pubmed.ncbi.nlm.nih.gov/17567829/

18. Devenyi P, Robinson GM, Kapur BM, Roncari DAK. High-density lipoprotein cholesterol in male alcoholics with and without severe liver disease. Am J Med. 1981;71:589–94.

19. Devenyi P, Kapur BM, Roy JHJ. High-density lipoprotein response to alcohol consumption and abstinence as an indicator of liver function in alcoholic patients. Can Med Assoc J. 1984;130:1445–7.

20. Trieb M, Horvath A, Birner-Gruenberger R, Spindelboeck W, Stadlbauer V, Taschner U, et al. Liver disease alters high-density lipoprotein composition, metabolism and function. Biochim Biophys Acta - Mol Cell Biol Lipids [Internet]. Elsevier B.V.; 2016 [cited 2020 Dec 17];1861:630–8. Available from: /pmc/articles/PMC5542032/?report=abstract

21. De Oliveira e Silva ER, Foster D, McGee Harper M, Seidman CE, Smith JD, Breslow JL, et al. Alcohol Consumption Raises HDL Cholesterol Levels by Increasing the Transport Rate of Apolipoproteins A-I and A-II. Circulation [Internet]. Lippincott Williams and Wilkins; 2000 [cited 2020 Aug 10];102:2347–52. Available from: https://www.ahajournals.org/doi/10.1161/01.CIR.102.19.2347

22. Li M, Diao Y, Liu Y, Huang H, Li Y, Tan P, et al. Chronic Moderate Alcohol Intakes Accelerate SR-B1 Mediated Reverse Cholesterol Transport. Sci Rep [Internet]. Nature Publishing Group; 2016 [cited 2020 Dec 17];6:1–11. Available from: www.nature.com/scientificreports

23. Kwon YJ, Kim SE, Park BJ, Bae JW, Kang HT. High-risk drinking is associated with dyslipidemia in a different way, based on the 2010–2012 KNHANES. Clin Chim Acta [Internet]. Elsevier B.V.; 2016 [cited 2020 Dec 17];456:170–5. Available from: https://pubmed.ncbi.nlm.nih.gov/27000703/

24. Ronksley PE, Brien SE, Turner BJ, Mukamal KJ, Ghali WA. Association of alcohol consumption with selected cardiovascular disease outcomes: A systematic review and meta-analysis. BMJ [Internet]. BMJ Publishing Group; 2011 [cited 2020 Dec 23];342:479. Available from: http://www.bmj.com/

25. Bell S, Daskalopoulou M, Rapsonamiki E, George J, Britton A, Bobak M, et al. Association between clinically recorded alcohol consumption and initial presentation of 12 cardiovascular diseases: Population based cohort study using linked health records. BMJ [Internet]. BMJ Publishing Group; 2017 [cited 2020 Dec 23];356:909. Available from: http://dx.doi.org/https://doi.org/10.1136/bmj.j909

26. Voight BF, Peloso GM, Orho-Melander M, Frikke-Schmidt R, Barbalic M, Jensen MK, et al. Plasma HDL cholesterol and risk of myocardial infarction: A mendelian randomisation study. Lancet [Internet]. Lancet Publishing Group; 2012 [cited 2020 Dec 23];380:572–80. Available from: https://pubmed.ncbi.nlm.nih.gov/22607825/

27. Holmes M V., Dale CE, Zuccolo L, Silverwood RJ, Guo Y, Ye Z, et al. Association between alcohol and cardiovascular disease: Mendelian randomisation analysis based on individual participant data. BMJ [Internet]. BMJ Publishing Group; 2014 [cited 2020 Dec 23];349. Available from: http://www.bmj.com/

28. Simon TG, Henson J, Osganian S, Masia R, Chan AT, Chung RT, et al. Daily Aspirin Use Associated With Reduced Risk For Fibrosis Progression In Patients With Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol [Internet]. W.B. Saunders; 2019 [cited 2020 Dec 17];17:2776–2784.e4. Available from: https://pubmed.ncbi.nlm.nih.gov/31077838/

29. Papaluca T, Craigie A, McDonald L, Edwards A, MacIsaac M, Holmes JA, et al. Non-invasive fibrosis algorithms are clinically useful for excluding cirrhosis in prisoners living with hepatitis C. PLoS One. Public Library of Science; 2020;15.

30. Innes H, Buch S, Hutchinson S, Guha IN, Morling JR, Barnes E, et al. Genome-Wide Association Study for Alcohol-Related Cirrhosis Identifies Risk Loci in MARC1 and HNRNPUL1. Gastroenterology [Internet]. W.B. Saunders; 2020 [cited 2020 Dec 30];159:1276–1289.e7. Available from: https://pubmed.ncbi.nlm.nih.gov/32561361/

31. Ginès P, Grauera I, Lammert F, Angeli P, Caballeria L, Krag A, et al. Screening for liver fibrosis in the general population: a call for action [Internet]. Lancet Gastroenterol. Hepatol. Elsevier Ltd; 2016 [cited 2020 Dec 23]. p. 256–60. Available from: https://pubmed.ncbi.nlm.nih.gov/28404098/

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.